Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 4 (B3GNT4) is an enzyme in the beta-1,3-N-acetylglucosaminyltransferase family, classified as a glycosyltransferase and encoded by the B3GNT4 gene in humans[4][5][6]. It is a type II transmembrane protein that preferentially uses lacto-N-neotetraose as a substrate and is involved in the synthesis of poly-N-acetyllactosamine chains, key components of glycoproteins and glycolipids important for cellular recognition and adhesion[5][6]. Consistent with the function of this enzyme family, B3GNT4 is essential in the biosynthesis of extended N-acetyllactosamine structures on glycoproteins, which play roles in modulating cell-cell interactions, immune response, and potentially in cancer progression, although direct disease links appear to be under-characterized in the available databases[4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 4 (B3GNT4).